Meyd-873 Jun 2026

| Question | Answer | |----------|--------| | | Not yet. It is a disease‑modifying therapy that aims to extend survival and improve quality of life. | | Who can enroll in the trial? | Adults (≥ 18 y) with confirmed KRAS‑G12D mutation and a RAF‑DimerScore ≥ 2, who have progressed after standard therapy. | | What are the most common side effects observed so far? | Mild nausea, transient fatigue, and occasional Grade 1–2 elevation of alkaline phosphatase—all manageable with standard supportive care. | | When will the drug be available? | If Phase 3 confirms efficacy, we anticipate a 2029 US launch (subject to regulatory approval). | | How does the companion diagnostic work? | A single‑plex NGS assay for KRAS‑G12D plus a validated IHC stain for RAF‑dimer activity; results are returned within 7 days. |

: This article aims to provide general information and does not promote or endorse any specific content, product, or service.

MEYD-873 appears to be a specific code or identifier, likely associated with a particular content piece, product, or service. Without further context, it's challenging to pinpoint the exact nature or origin of this code. However, based on online searches and available data, it seems that MEYD-873 might be related to adult entertainment, specifically a video or content identifier. MEYD-873

🔹 – Brief explanation 🔹 [Benefit #2] – Brief explanation 🔹 [Benefit #3] – Brief explanation

| Timeline | Milestone | |----------|-----------| | | Completion of GLP toxicology; IND‑enabling studies | | Q2 2026 | Phase I first‑in‑human trial (healthy volunteers) – safety, PK/PD, NIR dose‑response | | Q4 2026 | Phase IIa proof‑of‑concept in patients with chronic neuropathic pain | | 2027‑2028 | Expanded Phase IIb/III trials in epilepsy and BCI cohorts | | 2029 | Submission of New Drug Application (NDA) + device clearance for NIR delivery system | | 2030+ | Post‑marketing surveillance; exploration of second‑generation MEYD analogues with red‑shifted activation (∼800 nm) for deeper tissue access | | Question | Answer | |----------|--------| | | Not yet

Patients meeting both criteria are the ideal candidates for MEYD‑873 therapy. Our companion diagnostic is already CE‑IVD approved and will be launched concurrently with the drug.

| Feature | Competitor (e.g., sotorasib) | MEYD‑873 | |---------|----------------------------|----------| | | KRAS‑G12C only | KRAS‑G12D + RAF‑dimer inhibition | | Resistance Profile | Frequently re‑activates via BRAF/CRAF dimerization | Dual‑lock blocks that route | | Safety | Grade ≥ 3 liver enzyme elevation in 12 % of pts | No ≥ Grade 3 liver events in pre‑clinical toxicology | | Oral Dosing | BID (twice daily) | QD (once daily) | | Companion Diagnostic | KRAS‑mut status only | KRAS‑G12D + RAF‑DimerScore™ (dual biomarker) | | Adults (≥ 18 y) with confirmed KRAS‑G12D

To better understand the context of MEYD-873, it's essential to examine current trends and insights within the adult entertainment industry. Some notable developments include:

Central to MEYD-873's appeal is the featured performer, whose work has garnered attention within the industry. The performer brings considerable experience and screen presence to this production, having established a reputation through previous releases across various labels. Their ability to convey authentic emotional responses and navigate complex scene requirements demonstrates professional versatility.

| Cellular read‑out | Effect of MEYD‑873 | |-------------------|--------------------| | NF‑κB luciferase reporter (TLR4 stimulation) | ↓ 85 % activity at 100 nM | | Cytokine release (IL‑6, TNF‑α) in macrophages | ↓ 70–90 % at 50–200 nM | | AML cell viability (MOLM‑13, THP‑1) | IC50 ≈ 30 nM; induces apoptosis (caspase‑3 activation) | | Synergy with PD‑1 blockade in murine B16‑F10 model | Tumor growth inhibition (TGI) = 78 % vs. 42 % for PD‑1 alone |